{"news_desk": "Letters", "print_page": "22", "subsection_name": null, "section_name": "Opinion", "byline": [], "abstract": null, "type_of_material": "Letter", "word_count": "145", "keywords": [{"rank": "1", "value": "Research", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Cancer", "is_major": "N", "name": "subject"}], "lead_paragraph": "The National Breast Cancer Coalition writes about drugs that have no clinical benefit and are priced out of patients\u2019 reach.", "pub_date": "2017-01-03T08:21:02+0000", "document_type": "article", "source": "The New York Times", "snippet": "The National Breast Cancer Coalition writes about drugs that have no clinical benefit and are priced out of patients\u2019 reach....", "multimedia": [], "web_url": "http://www.nytimes.com/2017/01/03/opinion/fruitless-drug-research.html", "slideshow_credits": null, "blog": [], "_id": "586b5ef495d0e03926078b69", "headline": {"main": "Fruitless Drug Research", "content_kicker": "Letter", "print_headline": "Fruitless Drug Research", "kicker": "Letter"}}